Drugmakers and, largely, the FDA argue that the medicines now being reviewed are different than the chemotherapies and blunter interventions of the past. This is having consequences for how clinical trials are being run, and for how much money drugmakers are investing in cancer R&D.

INCLUDED IN THIS TRENDLINE

– Radiopharmaceuticals for cancer: Making radiation precise
– After years of disappointment, cancer vaccines show new promise
– AstraZeneca study points to new uses for targeted cancer drug Enhertu